




an Open Access Journal by MDPI

Onco



[mdpi.com/
journal/
onco](https://mdpi.com/journal/onco)



Message from the Editor-in-Chief

Onco (ISSN 2673-7523) is an international peer-reviewed open access journal covering the whole field of oncotargets and cancer therapies research published quarterly online by MDPI.

Editor-in-Chief

Dr. Constantin N. Baxevanis

Aims

Onco (ISSN 2673-7523) is a peer-reviewed Open Access journal on oncotargets and cancer therapies, published online by MDPI. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

Scope

Onco functions as a scientific forum to integrate novel preclinical, translational and clinical cancer research with a primary focus on oncotargets and cancer therapies. The journal invites submissions of original research, reviews, editorials and commentaries covering a broad range of scientific domains, including (but not limited to):

- Cancer cell signaling;
- Cancer genetics and molecular targets;
- Cancer epigenetics and heterogeneity;
- Carcinogenesis and cancer evolution;
- Microbiome and cancer;
- Cancer metabolomics;
- Cancer biomarkers;
- Cancer dormancy;
- Novel targeted and immune cancer therapies;
- Randomized clinical trials;
- Oncotargets;
- Cancer therapies;
- Clinical reports proposing novel therapeutic regimens.

Short reports can be considered, provided that they present a clear relationship with one or more of the above topics.

Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The experimental details must be provided so that the results can be reproduced.

Onco's Editorial Board, consisting of international experts from leading institutions, oncology centers and universities in cancer research, aims to promote the evolving field of oncology.

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 27.8 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID



Editorial Office

onco@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

January 2025

